EP Wealth Advisors LLC Sells 252 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

EP Wealth Advisors LLC lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,132 shares of the medical research company’s stock after selling 252 shares during the period. EP Wealth Advisors LLC’s holdings in Charles River Laboratories International were worth $209,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CRL. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Optiver Holding B.V. acquired a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $37,000. GeoWealth Management LLC increased its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Charles River Laboratories International in the 4th quarter worth approximately $48,000. Finally, Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the period. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42% increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Down 3.3%

Shares of CRL opened at $139.20 on Thursday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company has a market capitalization of $6.84 billion, a PE ratio of 928.00, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The stock has a fifty day simple moving average of $136.67 and a two-hundred day simple moving average of $165.60. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the company earned $2.27 EPS. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on CRL shares. Mizuho lowered their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 9th. The Goldman Sachs Group lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, UBS Group reiterated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $172.31.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).